Mylan N.V., MYL is in the exchange NASDAQ and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Mylan N.V., MYL has a market cap of 21981.75. Since its IPO date on the 12/18/1987, Mylan N.V., MYL performance year to date is -19.59%. Today Mylan N.V., MYL has gained -1.86%, with a current price of 42.67.
Ownership of the company is 0.70% for insider ownership while institutional ownership is 71.30%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 3.60%, with return on investment at 8.20%.
In terms of debt levels and profit levels, Mylan N.V., MYL is seeing a long-term debt/equity of 0.62. While Total debt/equity is 0.73. With a profit margin of 8.30%, this is combined with a gross margin of 44.50%, and operating margin of 14.60%. Mylan N.V. ability to meet debt levels, with a current ratio of 1.7, while the quick ratio is 1.1.
For the last year Mylan N.V., MYL has seen a EPS growth of -31.50%. A performance for the year of -37.99%. The 52-week high is -42.26%, and the 52-week low is 13.51%. The average volume for Mylan N.V., MYL is 2047174.
With a target price of 58.13, can Mylan N.V., MYL reach this target? Looking at the value indicators of Mylan N.V., MYL. Mylan N.V. has a P/E of 27.8 and a forward P/E of 7.42. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.99. Mylan N.V. also has a P/S and a P/B of 2.25 and 2.07 respectively. For P/cash, Mylan N.V. has a value of 18.33, while it is 15.1 for P/free cash flow.
At the current price of 42.67, Mylan N.V. has a dividend yield of *TBA. We see a return on equity of 8.20%.
Looking more long-term Mylan N.V., is projected to get an EPS growth for the next five years of 13.98%. In the short-term an EPS growth of 18.56% in the next year is forecasted. This is after a EPS growth of -31.50% for this year and for the last five years a 20.20% growth has been seen.